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Role of platelet activating factor in gentamicin and cisplatin nephro-
toxicity. The present study was undertaken to evaluate the effects of
platelet activating factor (PAF) antagonists on nephrotoxicity induced
by gentamicin (GENTA) and cisplatin (DDP) in rats. PAF infusion
provoked a 56% decline in single nephron (SN) GFR due to a decrease
in glomerular plasma flow (QA, 55%), glomerular transcapillary hydrau-
lic pressure (iSP, 13%), and glomerular ultrafiltration coefficient (Kr,
37%). Four days after a single dose of DDP (6 mg/kg, i.p.) we observed
non-oliguric acute renal failure (ARF) with reduced SNGFR (45%), QA
(46%) and P (10%) and unchanged Kf. GENTA administration for 10
days (40 mg/kg, i.p. daily) induced a decline in SNGFR (40%), QA (41%)
and Kf(41%). Chronic treatment with a GENTA + PAF antagonist (BN
52021) partially prevented the decline in SNGFR (22%) by an amelio-
ration in QA (25%) and K (13%). However, simultaneous treatment
with DDP and BN 52063 completely prevented the ARF induced by
DDP, normalizing all parameters of renal function. Thus, PAF may be
a potential mediator involved in the nephrotoxicity induced by GENTA
and DDP.
Platelet activating factor (PAF) is a lipid mediator involved in
several renal disorders [1], with immune, inflammatory and
vasoactive effects on the kidney [1—3]. PAF causes a decline in
total renal glomerular filtration rate (GFR) and renal plasma
flow (RPF) due to arteriolar vasoconstriction and/or an effect on
mesangial cell contraction 12, 4, 5]. Continuous intravenous
infusion of PAF induces a decline in single nephron (SN) GFR
and in glomerular plasma flow (QA), accompanied by an in-
crease in arteriolar resistance and a decrease in glomerular
ultrafiltration coefficient (Kf) [4]. We have previously observed
that administration of the PAF antagonist BN 52021 minimizes
cyclosporine (CsA) nephrotoxicity by an amelioration of the
vasoconstriction induced by CsA [6]. Thus, PAF appears to
play a role in certain types of acute renal failure (ARF).
Cis-diamminedichloroplatinum (cisplatin, DDP) has proved
to be a valuable agent in oncologic therapy [7]. However, the
drug has many adverse side effects, nephrotoxicity being the
most common and important one [8]. The decrease in GFR in
DDP-induced ARF is due to reduced renal blood flow and
effective filtration pressure [9]. Similarly, the aminoglycoside
antibiotic, gentamicin, produces ARF associated with renal
hemodynamic alterations leading to decreases in QA and Kf,
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with an increase in arteriolar resistances [10, 11]. These findings
suggest that the ARF induced by both DDP and gentamicin
presents a glomerular hemodynamic pattern similar to that
induced by PAF [4]. Thus, the present study was undertaken to
evaluate the effects of PAF antagonists on ARF caused by both
cisplatin and gentamicin.
Methods
Studies were performed on 55 Munich-Wistar rats weighing
250 to 330 g. Animals were allowed free access to water and a
standard rat pellet diet until the morning of the study. After the
control study period, Group 1 (N = 7) received continuous PAP
infusion (0.0125 0.001 p.g/kg body wt/min, i.v., Institut Henri
Beaufour, Les Ulis, France) at the maximum dose which did
not cause a decrease in mean arterial pressure (MAP) below the
autoregulation level (MAP < 75 mm Hg). Group 2 (N 8)
received saline i.p. (0.3 to 0.5 ml) daily and served as a control
for groups 4 and 6. Group 3 (N = 7), was submitted to chronic
administration of the PAF antagonist BN 52021(20 mg/kg body
wt, i.p.) or BN 52063 (50 mg/kg body wt, p.o., twice a day,
Institut Henri Beaufour) to determine the chronic effects of BN
on the renal function of normal euvolemic rats. In group 4 (N =
9) the animals received a single dose of cisplatin (6 mg/kg body
wt i.p., Laborterapica Bristol, São Paulo, Brazil) and clearance
and micropuncture studies were performed four days later.
Group 5 (N = 7) received the same dose of cisplatin and daily
treatment with BN 52063 (50 mg/kg body wt, p.o., twice a day)
for four days. After that, the same protocols were followed.
The animals of Group 6 (N = 9) received gentamicin (40
mg/kg body wt, i.p., Schering Laboratories, São Paulo, Brazil)
for 10 days and were then evaluated for glomerular hemody-
namics. Finally, Group 7 (N = 8) received the same dose of
gentamicin plus BN 52021 (20 mg/kg body wt, i.p.) over 10
days, followed by evaluation of glomerular hemodynamics.
General Protocol
Rats were anesthetized with mactin, 100 mg/kg body wt, i.p.
(BYK Gulden, Konstanz, Germany), placed on a temperature
regulated micropuncture table and monitored with an electronic
thermometer (Simpson Co. Chicago, Illinois, USA) to maintain
their rectal temperature between 36.5 to 37.5°C, After trache-
otomy, the left femoral artery was catheterized with a PE-50
polyethylene tube and approximately 60 d of arterial blood was
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Table 1. Summary of whole kidney function
BW1 BWf
g
KW
CA gidi
Hct Hct1
%
MAP
mm Hg V' pJ/min
GFR RPF
mi/mm FF
Before 295 13 — 0.95 0.06 5.1 0.1 46 1 45 1 99 2 6.4 0.5 1.09 0.03 3.59 0.17 0.30 0.01
PAF
AfterPAF — — — 5.2 0.1 — 47 1 87 It 2.4 05b 0.43 0.10k' 1.90 038b 0.24 O.O2
(N=7)
Saline1 298 8 298 8 0.95 0.03 5.1 0.1 45 1 44 I 98 2 5.9 0.9 1.08 0.04 3.53 0.28 0.32 0.02(N = 8)
BNchron 269 12 268 13 0.88 0.05 5.3 0.1 48 1 46 1 103 1 3.1 0.4 0.98 0.05 3.12 0.18 0.32 0.01(N = 7)
DDP 293 8 267 7 1.06 0.03 4.9 0.2 46 1 46 1 105 2 12.4 2.2c 0.33 0.04 0.86 0.27c 0.49 0.07c
(N = 9)
DDP + 286 9 270 10 0.97 0.06 5.4 0.2 44 1 43 1 98 3 12.8 34C 1.03 005d 3•49 017d 0.30 002d
BNehron(N =7)
GENTA 270 6 265 6 0.96 0.03 5.0 0.1 46 1 45 1 105 3 4.9 0.8 0.56 0.05c 1.73 0.16c 0.32 0.02
(N = 9)
GENTA + 272 7 268 8 0.97 0.06 5.1 0.1 47 1 46 1 109 7 5.9 1.7 0.79 0.06 2.38 0.20 0.34 0.02
BNchron(N = 8)
Data are presented as X SE.
Abbreviations are in the text.
a p < 0.05, BWf vs. BW10b P < 0.05, before vs. after PAF
P < 0.05 vs. sa1ine,d p < 0.05, DDP + BNchrofl vs. DDP
P < 0.05, GENTA + BNchrO vs. GENTA
collected for baseline hematocrit (Hct) and protein (CA) deter-
minations. This artery was also used for periodic blood sam-
pling and estimation of MAP. Polyethylene catheters were also
inserted into the right and left jugular veins. A saline solution
containing inulin (10%), and p-aminohippuric acid (2%) (PAH)
was immediately infused into the right side at a rate of 1.2 mI/hr
and maintained throughout the experiment to determine GFR
and renal plasma flow (RPF). Isoncotic rat serum was infused
into the left jugular vein to replace surgical losses in order to
maintain the animals under euvolemic conditions [12]. Laparot-
omy was then performed and a PE-lO polyethylene tube was
introduced into the left ureter for collection of timed urine
samples (V'). To prepare rats for micropuncture, the posterior
face of the kidney was dissected free, supported on a small
plastic shovel and positioned to avoid interference by dia-
phragm movements.
After a 30 to 45 minute equilibration period, the initial study
period was begun. Two urine samples and blood samples were
collected for determination of Hct, CA, inulin and PAH in
plasma and urine, and the procedure was repeated during the
second study period.
Samples of fluid from surface proximal tubules were collected
for determination of flow rate and inulin concentration, fol-
lowed by calculation of single nephron glomerular filtration rate
(SNGFR). Hydraulic pressures were measured in surface gb-
merular capillaries (P), proximal tubules (PT), efferent arte-
rioles (PEA), and peritubular capillaries (Pa) with a continuous
recording servonull micropipette transducer system (1PM Inc.
San Diego, California, USA); the results were reported as
average. To estimate the pre- and postglomerular colloid os-
motic pressures, protein concentration in femoral arterial and
efferent arteriolar plasma were measured as described previ-
ously [131. These estimations permitted the calculation of single
nephron filtration fraction (SNFF), initial gbomerular capillary
plasma flow rate (QA), afferent (RA), efferent (RE) and total (RT)
arteriolar resistance, and gbomerular capillary ultrafiltration
coefficient (K1), using equations previously described [13, 14].
Analytical procedures
Plasma and urinary inulin concentrations were determined by
the macroanthrone method of Fuhr, Kaczmarczyk and Krutt-
gen [15]. PAH concentration was determined by the Bratton
and Marshal method modified by Smith et al [16]. Inulin
concentration in tubular fluid was measured by the microfluo-
rescence method [17]. Protein concentrations in efferent arteri-
olar and femoral arterial plasma were determined by the fluo-
rimetric method [181. Whole kidney filtration fraction (FF) was
calculated as the GFR/RPF ratio.
Statistical analysis was performed by the paired Student's
t-test and by one-way analysis of variance with Duncan and
Tukey's test. Significance was defined as P < 0.05. Data are
presented as mean (X SE).
Results
Table I summarizes the results of whole kidney function.
Initial body weight (BW1), kidney weight (KW), afferent pro-
tein concentration (CA), initial (Hct1) and final hematocrit
(Hctffl) did not differ among groups. PAF infusion caused a
decline in MAP (99 2 to 87 1 mm Hg, P < 0.05) and urine
flow rate (V'; 6.4 0.5 to 2.4 0.5 d/min, P < 0.05). In
addition, significant decreases in GFR (1.09 0.03 to 0.43
0.10 mI/mm, P < 0.05) and RPF (3.59 0.17 to 1.90 0.38
mI/mm, P < 0.05) were observed. Since the decrease in GFR
(61%) was greater than that observed for RPF (47%), FF
decreased significantly (0.30 0.01 to 0.24 0.02, P < 0.05).
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Table 2. Summary of superficial nephron function
SNGFR QA SNFF
%
GC "T s"
ni/mm mm Hg
Before PAF 31.1 2.7 96.7 7.6 33 2 46 1 14 1 32 I
After PAF 13.8 1.9 43.3 6.5 33 3 42 la 14 1 28 ta(N = 7)
Saline1,,(N =8)
BNchron(N=7)
DDP
36.8 2.6
30.8 2.3
19.7 1,6b
112.1 8.1 33 2
102.5 8.5 31 2
61.2 5.5" 33 3
46
48
41
1
1
1b
15 1
16 1
14 2
31 1
32 1
28 1t(N = 9)
DDP + BNcron(N=7)
GENTA
35.1 2.1c
21.9 1,7b
120.4 12.0c 31 3
66.2 5.01) 33 1
43
47
1
1
1b
16 1
32 ic
31 I
(N = 9)
GENTA + BNcron
(N = 8)
28.6 24b,d 83.5 6.3" 34 2 47 1 16 1 31 1
Table 2. Continued
A ITE RA RE RT K1
ni/sec mm Hg DIEmm Hg X 1010 dyn sec cm5
16.0 0.4 29.7 1.6 2.54 0.26 1.72 0.15 4.26 0.40 0.063 0.006 6/1
16.3 0.3 30.4 2.3 4.71 O.49a 3.17 0.38a 7.88 0.82a 0.040 0.005a 3/3
15.8 0.4 29.3 1,0 2.18 0.22 1.50 0.14 3.68 0.35 0.082 0.012 4/4
16.7 0.6 29.1 0.7 2.42 0.2 1.59 0.37 4.01 0.37 0.064 0.009 7/0
15.3 0.7 28.0 0.8 4.68 0.52" 2.27 031b 6.96 077b 0.063 0.016 3/6
17.4 0.8 30.8 1.1 2.21 0.26c 1.46 0.21c 3.67 0.46c 0.076 0.005 5/2
15.7 0.3 29.1 1.0 4.09 0.35" 2.28 0.18" 6.37 044b 0.048 0.007" 613
16.1 0.3 31.2 1.9 3.32 0.26 1.73 0.16 5.04 0.36 0.071 0.008" 6/2
Data are presented as X se. DIE, number of animals in filtration disequilibrium (irIP < 1) and equilibrium, respectively; other abbreviations
are in the text.
a P < 0.05, before vs. after PAF
b P < 0.05 vs. saline,,
P < 0.05, DDP + BNchrOn vs. DDP
"P < 0.05, GENTA + BNcron VS. GENTA
Daily BN administration to control rats did not change any
parameter of whole kidney or single nephron function.
The animals treated with DDP showed a significant decrease
in body weight after four days of treatment (293 8 to 267 7
g, P < 0.05). Moreover, DDP treatment induced a marked
increase in V' (12.4 2.2 vs. 5.9 0.9 jsl/min, P < 0.05) when
compared to the saline,, group. Despite the increase in urinary
volume, DDP caused a decline in both GFR (0.33 0.04 vs.
1.08 0.04 mlimin, P <0.05) and RPF (0.86 0.27 vs. 3.53
0.28 mI/mm, P < 0.05). Since the decrease in RPF was higher
than that observed for GFR, FF increased significantly (0.32
0.02 to 0.49 0.07, P < 0.05).
Striking changes were observed after simultaneous treatment
with DDP and BN 52063. Mean GFR (1.03 0.05 vs. 1.08
0.04 mI/mm) and RPF (3.49 0.17 vs. 3.53 0.28 mI/mm)
returned to normal levels when compared to the saline1, group.
However, V' remained elevated (12.8 3.4 vs. 12.4 2.2
p11mm).
Rats which received GENTA showed a reduction in GFR
(0.56 0.05 vs. 1.08 0.04 ml/min, P < 0.05) and RPF (1.73
0.16 vs. 3.53 0.28 ml/min, P < 0.05) when compared to the
saline1,, group. After treatment with BN 52021, the animals
showed an increase in both GFR (0.56 0.05 to 0.79 0.06
mi/mm, P < 0.05) and RPF (1.77 0.16 to 2.38 0.20 mI/mm,
P < 0.05) when compared to the GENTA group, but these
values were still significantly below those for the saline,,, rats.
Table 2 summarizes the results of superficial nephron func-
tion for all groups. PAF infusion caused a decrease in SNGFR
(31.7 2.7 to 13.8 1.9 nI/mm, P < 0.05), and a reduction in
QA (96.7 7.6 to 43.3 6.5 nI/mm, P < 0.05) and P (32 1
to 28 1 mm Hg, P < 0.05). Since T (14 ito 14 1 mm Hg)
remained unaltered, the decrease in P was accounted by the
reduced P0, (46 ito 41 1 mm Hg, P <0.05). Neither EA
(16 1 to 17 1 mm Hg) nor Pc (8 1 to 9 1 mm Hg) was
affected. An impressive increment in both RA (2.54 0.26 to
4.71 0.49 x 1010 dyn sec cm5, P < 0.05) and RE (1.72 ±
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0.05 to 3.17 0.38 x i0l dyn sec cm5, P < 0.05) was
observed. Mean Kf was reduced by 40% from 0.063 0.006 to
0.040 0.005 ni/sec mm Hg (P < 0.05). When we considered
unique K values (N = 3 both before and after PAF adminis-
tration), a similar decrease was observed from 0.060 0.006 to
0.030 0.011 nllsec mm Hg.
As observed for PAF infusion, DDP-treated rats showed a
decline in SNGFR (19.7 1.6 vs. 36.8 2.6 nI/mm, P <0.05),
QA (61.2 5.5 vs. 112.1 8.1 nI/mm, P < 0.05) and P (28
1 vs. 31 1 mm Hg, P < 0.05) when compared the to the
sa1ine1 group. However, Kf remained unchanged (0.063
0.016 vs. 0.082 0.012 nllsec mm Hg, P> 0.05) despite an
—25% reduction, even though we evaluated only unique K
(0.051 0.0 16 vs. 0.087 0.012 nlisec mm Hg). DDP caused
increases in both RA (4.68 0.52 vs. 2.18 0.22 X i0
dyn . sec cm5,P<0.05) and RE (2.27 0.31 vs. 1.50 0.14
x 1010 dyn sec cm5, P <0.05). This preferential increase in
RA led to a decline in mean P0 (43 1 vs. 46 1 mm Hg)
which, however, was not significant.
After simultaneous treatment with DDP and BN 52063, we
observed a normalization in all parameters of superficial neph-
ron function. SNGFR (35.1 2.1 vs. 36.8 2.6 nI/mm), QA
(120.4 12.0 vs. 112.1 8.1 ni/mm), P (32 1 vs. 31 1 mm
Hg) and RT (3.67 0.46 vs. 3.68 0.35 x 1010
dyn sec cm5) returned to control values. Moreover, mean
values (0.076 0.05 vs. 0.063 0.016 nI/sec mm Hg) or
unique values of Kf (0.076 0.005 vs. 0.051 0.016 nIl
sec mm Hg) only presented a slight increase.
In the GENTA group, SNGFR (21.9 1.7 vs. 36.8 2.6
nllmin, P < 0.05), QA (66.2 5.0 vs. 112.1 8.1 ni/mm, P <
0.05) and mean Kf (0.048 0.007 vs. 0.082 0.012 ni/sec mm
Hg, P < 0.05) or unique Kf (0.045 0.007 vs. 0.087 0.012
ni/sec mm Hg, P < 0.05) decreased significantly. Mean iP
remained unchanged (31 1 vs. 31 1 mm Hg). Neither EA
(19 1 vs. 17 1 mm Hg) nor Pc (9 1 vs. 10 1 mm Hg) was
affected. Pre- and postglomerular resistances increased propor-
tionally, leading to a significant elevation (73%) in RT (6.37
0.44 vs. 3.68 0.35 x 10's dyn sec cm, P < 0.05) when
compared to saline1 treated rats.
Simultaneous treatment with GENTA and BN 52021 in-
creased Kf (0.071 0.008 vs. 0.047 0.007 nllsec mm Hg, P
<0.05) and SNGFR (28.6 2.4 vs. 21.9 1.7 ni/mm, P. <
0.05), respectively, when compared to GENTA alone. The
changes in QA (83.5 6.3 vs. 66.2 5.0 nI/mm, P> 0.05) and
arteriolar resistances did not reach statistical significance. De-
spite the 31% increase in SNGFR after BN52021 treatment, this
value still remained below the saline1 level.
Discussion
Since the discovery of platelet activating factor, several
studies have been undertaken to evaluate the role of this
mediator in renal disorders [1, 5]. PAF is produced by various
kidney cell types, including glomeruli and mesangial and med-
ullary renal cells [3, 19]. GFR and RPF were decreased after
PAF infusion during maintenance of MAP [2]. Moreover, PAF
caused a decrease in SNGFR, QA and Kf with an increase in
arteriolar resistances [4]. In the present study, we observed that
continuous PAF infusion provoked a significant decrease in
MAP, but was still within the range of renal autoregulation.
PAF caused a small decrease in P, although the increases in
both arteriolar resistances (RA and RE) were nearly propor-
tional. Since T remained unchanged, mean P decreased. The
increase in RE observed after PAF administration may be due,
at least in part, to the modest decline in arterial pressure.
However, the increase in RA with PAF is an effect of the
autacoid since RA would be expected to decline as arterial
pressure fell [20]. The reduction in SNGFR was caused by renal
vasoconstriction with a significant decline in QA. Moreover,
PAF appeared to decrease K, although only three of six
animals were in a condition of disequilibrium of filtration. Since
PAF can induce contraction of mesangial cells [211, its effects
on K may be caused by a direct action on PAF receptors in
these cells. A similar hemodynamic situation was observed
after acute renal failure induced by nephrotoxins [11, 22],
suggesting a potential role of PAF in many types of nephrotox-
icity. In fact, in previous studies from this laboratory, we
observed that a PAF antagonist prevented the vasoconstriction
induced by cyclosporine in superficial nephrons [6].
BN 52021 and BN 52063 are terpenes isolated from Gingko
biloba which significantly inhibit the immune and vascular
effects of PAF [23]. BN 52021 is a gingkolide A, while BN 52063
is an association of gingkolides A, B, and C, and both BNs have
the ability to block PAF effects [24, 25]. As observed for acute
BN administration to normal rats, when BN was given chron-
ically to euvolemic control animals it did not cause any changes
in whole kidney or superficial nephron function. These results
are very similar to those observed with other blockers such as
prostaglandin inhibitors [26] and angiotensin I converting en-
zyme inhibitor [11]. Thus, when euvolemic Munich-Wistar rats
are submitted to a hormonal blocking treatment, other hor-
monal systems are activated and a maintenance of renal func-
tion is achieved. Therefore, BN has no direct effects on kidney
function and represents a useful tool for the study of PAF
pathophysiology in several renal disorders.
Cisplatmn has a remarkable chemotherapeutic potential in a
variety of human neoplasms, changing the natural history of
many solid tumors [7, 27]. Since the kidney is highly susceptible
to toxic injury, it is not surprising that antineoplastic agents can
cause nephrotoxicity. Jones et al [28], using a similar dose of
cisplatin, observed that after 72 to 96 hours necrosis of the S3
segment of the proximal tubule was most pronounced and renal
function progressively worsened.
We observed that urinary volume doubled and was accom-
panied by a decrease in GFR, characterizing non-oliguric acute
renal failure. The polyuria observed after DDP treatment is
reported to occur in two phases. In the early phase (24 to 48 hr)
DDP induces a lower level of vasopressin release or synthesis
and high rates of prostaglandin production [29]. In the later
phase (72 to 96 hr) the renal concentrating ability is not
dependent on vasopressin or prostaglandin [29]. Probably, the
mechanism involved in the later polyuria is the lack of an
addition of urea to fluid in the loop of Henle. Contrary to the
addition of urea-to-loop fluid observed in normal rats, the
DDP-treated rats seem to reabsorb urea, generating a reversal
of the urea concentration gradient [30]. In fact, our data suggest
that PAF is strongly involved in DDP nephrotoxicity, since
normalization of renal function was achieved when BN was
used. However, we did not observe reversal of the polyuria
induced by DDP, suggesting that the mechanism(s) involved in
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urinary concentration are independent of the vasoconstriction
that caused ARF in DDP rats.
Moreover, in the present study, cisplatin administration
caused a significant decrease in GFR and RPF. The decrease in
GFR has been attributed to vasoconstriction of the renal
vessels, yielding decreases in renal plasma flow and effective
filtration pressure [9]. Significant increases in both afferent and
efferent arteriolar resistances were observed. The greater incre-
ment in RA caused a significant decrease in GC• Since T
remained unaltered, P decreased significantly. The latter data
may also indicate that intratubular obstruction was not the main
factor in cisplatin-induced ARF. It was previously observed
that intratubular obstruction does not play an important role in
the early phase of this ARF [9].
After volume expansion, renal plasma flow in cisplatin-
treated rats increased but not to control levels, while GFR and
SNGFR remained below control euvolemic values [31]. This
suggested that a possible reduction in K1, as well as the
decrease in the renal plasma flow, contributes to the reduced
GFR. However, in the present study K1 was not changed
significantly by cisplatin treatment, although it fell by approxi-
mately 25% when we used only unique K1, even though we did
not observe any statistical difference.
As observed in other studies [9, 32, 33], the decline in
SNGFR (45%) was disproportionately lower than that observed
for GFR (69%). There are many possible explanations for this
finding. It has been previously demonstrated that there is a leak
of inulin (about 30%) out of the tubule fluid beyond the site of
proximal tubule puncture [33]. Although we did not measure the
magnitude of this leak under our experimental conditions, other
workers have suggested that this leak is not enough to explain
the discrepancy between the values obtained for SNGFR and
GFR [33]. Another possibility is that when the nephrons were
selected for micropuncture, only nephrons lightly affected by
cisplatin were punctured (a biased selection). However, we did
not observe any apparent differences in surface morphology.
Thus, the most attractive explanation is that DDP exerted most
of its effects on juxtamedullary nephrons, leading to a severe
decrease in GFR and thus accounting for the observed discrep-
ancy in GFR and SNGFR values. Acute or chronic administra-
tion of captopril, an angiotensin I-converting enzyme inhibitor,
or verapamil, a calcium channel blocker, did not change the
evolution of cisplatin nephrotoxicity [30], thus suggesting that
both angiotensin and calcium were not mediators in this neph-
rotoxicity. In contrast, in the present study treatment with the
PAF antagonist BN 52063 completely prevented the DDP-
induced changes to both whole kidney and superficial nephron
functions. The increase in mean arteriolar resistances and the
decrease in P were abolished by simultaneous treatment with
BN 52063. Moreover, the glomerular plasma flow rate remained
unchanged and SNGFR returned to normal. Thus, this treat-
ment induced a striking change in DDP-induced ARF normal-
izing all parameters of renal function, including overall mortal-
ity and morphology without any alterations in cisplatin
pharmacodynamics [34]. PAF antagonists are not alone in
producing a beneficial effect on renal function in DDP treat-
ments. Atrial natriuretic peptide [35] and superoxide dismutase
[36] also partially prevent DDP nephrotoxicity.
Gentamicin is an important drug for the treatment of severe
gram-negative infections. However, a common side effect is
nephrotoxicity [37]. The renal injury leading to acute and
sometimes reversible renal failure frequently limits its useful-
ness. GENTA accumulation in the kidney can cause tubular cell
necrosis [38]. On the other hand, an important decline in renal
function has been observed in association with minimal mor-
phological alterations, suggesting that hemodynamic factors
may play a major role in gentamicin-induced ARF [10, 11].
Experimental studies have demonstrated that a reduction in
SNGFR in gentamicin-treated rats was due to a decline in QA
and K1 [10, 111. Our results indicate that the lower QA is caused
by an increase in both preglomerular and efferent arteriolar
resistances. This proportional increase in pre- and postglomer-
ular resistances accounts for the normal level of P. As also
observed for DDP, mean PT remained unaltered, excluding
tubular obstruction as an important factor in the pathophysiol-
ogy of GENTA-induced ARF. These results do not permit us to
distinguish between a reduction in hydraulic conductivity
and/or total glomerular capillary surface area as the main factor
involved in the lower K1. Luft et a! [391 suggested that a
decrease in size and number of glomerular endothelial fenestral
pores causes a reduction in surface area for filtration, leading to
reduced K1. Thus, in view of the similarities between the effects
of PAF and GENTA on renal microcirculation, we employed a
protocol involving simultaneous treatment with GENTA and
BN 52021. It was observed that ARF induced by GENTA was
minimized by the PAF antagonist. BN blunted the effects of
GENTA on SNGFR with an increase in QA and normalization
of K1. The increase in QA was caused by an amelioration of both
arteriolar resistances, although these changes did not reach
statistical significance. Since PAF can contract mesangial cells
[21], the lower K1 induced by gentamicin may have been
mediated by PAF actions on mesangial cells. However, others
have observed that K1 returned to normal levels in animals
treated with GENTA plus captopril [11], suggesting that angi-
otensin II formation also plays a role in this nephrotoxicity.
Recently, Neuwirth and coworkers [40] suggested that angio-
tensin II stimulated PAF production in cultured rat mesangial
cells. Thus the protective effect of captopril on K1 observed by
Schor et a! [11] may be mediated by lower PAF production.
The similar, but not identical, glomerular hemodynamic
effects of PAF, DDP and GENTA suggest a participation of
PAF in these nephrotoxic events. However, it would be inter-
esting to compare the renal microcirculation responses after
DDP and GENTA with an identical hemodynamic control
group.
In summary, PAF acts on the renal microcirculation leading
to a reduced SNGFR due to a declines in QA. P and K1.
Simultaneous treatment with a PAF antagonist and GENTA
significantly minimized the nephrotoxicity induced by this
aminoglycoside. Moreover, when BN and DDP were combined
the cisplatin-induced alterations in glomerular hemodynamics
were completely blunted. Thus, PAF appears to play a role in
nephrotoxicity mediated by GENTA or DDP, and BN could be
a useful means to prevent this phenomenon.
Acknowledgments
These studies were supported in part by grants from Fundacao de
Amparo a Pesquisa do Estado de São Paulo-FAPESP, Instituto Paulista
de Estudos e Pesquisas em Nefrologia e Hipertensão-IPEPENHI,
Pavao dos Santos et a!: PAF in gentamicin and cisplatin nephrotoxicity 747
Conseiho Nacional de Desenvolvimento CientIfico e TecnolOgico-
CNPq, and Institut Henri Beaufour, Les Ulis, France.
Reprint requests to Nestor Schor, M.D., Ph.D., Nephrology Divi-
sion, Department of Medicine, Escola Paulista de Medicina, Rua
Botucatu, 740, 04023 São Pau/o-SP, Brazil.
References
1. SCHLONDORFF D, NEUWIRTH R: Platelet-activating factor and
kidney. Am J Physiol 251:Fl—Fll, 1986
2. VEMULAPALLI S, CHIu PJS, BARNETT A: Cardiovascular and renal
action of platelet-activating factor in anesthetized dogs. Hyperten-
sion 6:489—493, 1984
3. PIROTZKY E, NINI0 E, BIADAULT J, PFISTER A, BENVENISTE J:
Release of platelet activating factor, slow-reacting substance, and
vasoactive amines from isolated rat kidneys. Kidney mt 25:404—
410, 1984
4. BADR KF, DEBOER DK, TAKAHASHI K, HARRIS RC, FoGo A,
JACOBSON HR: Glomerular responses to platelet activating factor in
the rat: Role of thromboxane A2. Am J Physiol 256:F35—F43, 1989
5. SCHOLONDORFF D, SATRIANO JA, HAGESE J, PEREZ J, BAUD L:
Effect of platelet activating factor and serum-treated zymosan on
prostaglandin E2 synthesis, arachidonic acid release and contrac-
tion of cultured rat mesangial cells. J C/in Invest 73:1227—1231, 1984
6. SANTOS OFP, B0IM MA, BREGMAN R, DRAIBE SA, BARROS EJG,
PIROTZKY E, SCHOR N, BRAQUET P: Effect of platelet activating
factor antagonist on cyclosporin nephrotoxicity: Glomerular hemo-
dynamics evaluation. Transplant 47:592—595, 1989
7. EINHORN LH, WILLIAMS SD: Current concepts in cancer: The role
of cisplatinum in solid tumor therapy. N Eng/ J Med 300:289—291,
1979
8. RIEs F, KATSTERSKY J: Nephrotoxicity induced by cancer chemo-
therapy with special emphasis on cisplatin toxicity. Am J Kid Dis
8:368—378, 1986
9. WINSTON JA, SAFIRSTEIN R: Reduced renal blood flow in early
cisplatin-induced acute renal failure in the rat. Am J Physiol
249:F490—F496, 1985
10. BAYLIS C, RENNKE HG, BRENNER BM: Mechanisms of the defects
in glomerular ultrafiltration associated with gentamicin administra-
tion. Kidney mt 12:344—353, 1977
11. SCHOR N, ICHIKAWA I, RENNKE HG, TROY JL, BRENNER BM:
Pathophysiology of altered glomerular function in aminoglycoside-
treated rats. Kidney mt 19:288—296, 1981
12. MADDOX DA, PRICE DC, RECTOR FC JR: Effects of surgery on
plasma volume and salt and water excretion in rats. Am J Physiol
233:F600—F606, 1977
13. DEEN WM, ROBERTSON CR, BRENNER BM: A model of glomerular
ultrafiltration in the rat. Am JPhysiol 223:1178—1 183, 1972
14. DEEN WM, ROBERTSON CR, BRENNER BM: Dynamics of glomer-
ular ultrafiltration in the rat: IV Determination of ultrafiltration
coefficient. J C/in Invest 52:1500—1508, 1973
15. FUHR J, KACZMARCZYK J, KRUTTGEN CD: Eine einfache colorime-
trishe Methode zur Inulin Bestimmung fur Nierenclearanceunter-
suchungen bei Soff wechselgesumden und Diabetikern. Kim
Wochenschr 33:729—730, 1955
16. SMITH HW, FILKELSTEIN N, ALIMINOSA L, CRAWFORD B, GRA-
BER M: The renal clearances of substituted hippuric acid derivates
and other aromatic acids in dog and man. J Clin Invest 24:388—404,
1945
17. VUREK GG, PEGRAM SE: Fluorimetric method for the determina-
tion of nanogram quantities of inulin. Anal Biochem 88:513—521,
1978
18. VIETS JW, DEEN WM, TROY JL, BRENNER BM: Determination of
serum protein concentration in nanoliter blood samples using
fluorescamine or o-phthalaldehyde. Anal Biochem 88:513—521, 1978
19. PIROTZKY E, NINIO E, BIADAULT J, PFISTER A, BENVENISTE J:
Biosynthesis of platelet activating factor VI. Precursor of platelet
activating factor and acetyltransferase activity in isolated rat kid-
ney cells. Lab Invest 5 1:567—572, 1984
20. ROBERTSON CR, DEEN WM, TROY JL, BRENNER BM: Dynamics of
glomeular ultrafiltrationo in the rat. III Hemodynamics and auto-
regulation. Am J Physiol 223:1191—1200, 1972
21. EGIDO J, MAMPASO F, RODRIGUEZ MJ, MARTINEZ JC, MENDI-
LUCE A, HERNANDO P, HERNANDO L: Papel de los antagonistas del
factor activador de las plaquetas (PAF) en Ia nefrotoxicidad induz-
ida por Ia ciclosporina en ratos. Nefrologia VIII (suppi l):30—37,
1988
22. BARROS EJG, B0IM MA, AJZEN H, RAM0S OL, SCHOR N: Glomer-
ular hemodynamics and hormonal participation on cyclosporine
nephrotoxicity. Kidney mt 32:19—25, 1987
23. BRAQUET P, SPINNEWYN B, BRAQUET M, BOURGAIN RH, TAYLOR
JE, ETIENE A, DRIEU K: BN52021 and related compounds: New
series of highly specific PAF-acether receptor antagonists isolated
from Gin gko biloba. Blood Ves 16:558—572, 1985
24. BRAQUET P: The gingkolides: Potent platelet activating factor
antagonists isolated from Gingko biloba I: Chemistry, pharmachol-
ogy and clinical application. Drugs of the Future 12:643—699, 1987
25. SAUDERS RN, HUNDLEY DA: Platelet activating factor antagonists.
Ann Rev Pharmachol Toxicol 27:237—255, 1987
26. SCHOR N, ICHIKAWA I, BRENNER BM: Mechanism of action of
various hormones and vasoactive substances on glomerular ultrafil-
tration in the rat. Kidney mt 20:442—451, 1981
27. WITTES RE, CVITKOVIC E, SHAH J, GEROLD F, STRONG F:
Cisdichlorodiammine platinum (II) in the treatment of epidermoid
carcinoma of the head and neck. Cancer Treat 6 1:359—366, 1977
28. JONES TW, CHOPRA 5, KAUFMAN JS, FLAMENBAUM W, TRUMP
BF: Cisdiamminedichioroplatinum, (11)-induced acute renal failure
in the rat. Correlation of structural and functional alterations. Lab
Invest 52:363—374, 1985
29. CLIFTON G, PEARCE C, O'NEIL WS, WALLIN SD: Early polyuria in
the rat following single dose cis-dichlorodiammine platinum. J Lab
Clin Med 100:659—670, 1982
30. SAFIRSTEIN R, MILLER F, DIKMAN S, LYMAN N, SHAPIRO C:
Cisplatin nephrotoxicity in rats: Defect in papillary hypertonicity.
Am J Physiol 241:F175—F185, 1981
31. SAFIRSTEIN R, WINSTON J, GOLDSTEIN M, MOEL D, DIKMAN S,
GUTTENPLAN J: Cisplatin nephrotoxicity. A,n J Kid Dis 8:356—367,
1986
32. CHOPRA 5, KAUFMAN iS, JONES TW, HONG WK, GEHR MK,
HAMBUGER RJ, FLAMENBAUM WS, TRUMP BF: Cis-diam-
mininedichloroplatinum-induced acute renal failure in the rat. Kid-
ney In! 21:54—64, 1982
33. SAFIRSTEIN R, MILLER P. DIKMAN S: Cisplatin nephrotoxicity in
rats, in Acute Renal Failure, edited by Eliahou HE, London, John
Libbey, 1981, pp. 91—95
34. PIROTZKY E, BRAQUET P: Effect of PAF-antagonists in various
models of nephrotoxicity in the rat. Taipei Satellite Symposium of
the 3rd International Confrrence on PAF 1989, p. 29
35. CAPARRO G, ANASTASIA P, GIORDANO F, LONG JF, RUFOLO A, DE
SANTO NG: Atrial natriuretic factor increases glomerular filtration
rate in the experimental acute renal failure induced by cisplatin.
Adv Exp Med Biol 2 12:285—294, 1987
36. MCGUINESS JE, PROCTOR PH, DEM0P0uLO5 HJ, HOKANSON SA,
KIRKPATRICI-I DS: Amelioration of cis-platinum nephrotoxicity by
orgotein (superoxido dismutase). Physiol Chem Phys 10:367—377,
1978
37. Hou SH, BUSHINSKY DA, WIsH JB, COHEN JJ, HARRINGTON JT:
Hospital-acquired renal insufficiency: A prospective study. Am J
Med 74:248—253, 1983
38. SENEKJIAN HO, KNIGHT TF, WEINMAN EJ: Micropuncture study
of the handling of gentamicin by the rat kidney. Kidney mm
19:416—423, 1981
39. LUFT FC, WILLIS LR, RANKIN LI, EVAN AP: Salt-susceptible
hypertension following gentamicin-induced glomerular injury. (ab-
stract) C/in Res 27:674A, 1979
40. NEUWIRTH R, SATRIANO JA, DE CANDIDO S, CLAY K, SCHLON-
DORFF D: Angiotensin II causes formation of platelet activating
factor in cultured rat mesangial cells. Circ Res 64:1224-1229, 1989
